GlassScriptPhysician profile
Audrey T Summers
NPI 1972006955
$3,000.63
in general payments reported to CMS, 2019-2025
13 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $464 · 2022: $665 · 2023: $1,113 · 2024: $645 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,870.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $513.94 | 2022-2023 | Austedo Xr, Uzedy |
| Abbvie INC. | $427.72 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $411.96 | 2021-2022 | |
| Sage Therapeutics, LLC | $291.19 | 2022-2023 | |
| Bioxcel Therapeutics, INC. | $288.71 | 2023 | Igalmi |
| Neurocrine Biosciences, INC. | $256.95 | 2022-2023 | Ingrezza |
| Livanova USA, INC. | $145.07 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| E.R. Squibb & Sons, L.L.C. | $127.26 | 2024 | |
| Tris Pharma INC | $124.99 | 2023 | Dyanavel Xr, Quillivant, Quillichew Er |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $115.83 | 2021 | |
| Acadia Pharmaceuticals INC | $114.23 | 2022 | |
| Biogen, INC. | $96.80 | 2024 | |
| Novo Nordisk INC | $85.98 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audrey Summers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.